Who are Placebo-Apremilast's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eucrisa, Roflumilast conventional dosage, metformin and roflumilast, Oral roflumilast, Roflumilast Foam, Roflumilast Foam 0.3%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-apremilast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Placebo-Apremilast — Competitive Intelligence Brief

Placebo-Apremilast (Placebo-Apremilast) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-4 (PDE-4) inhibitor. Area: Immunology.

marketed Phosphodiesterase-4 (PDE-4) inhibitor PDE-4 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo-Apremilast (Placebo-Apremilast) — Amgen. Apremilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo-Apremilast TARGET	Placebo-Apremilast	Amgen	marketed	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Eucrisa	Crisaborole	Anacor Pharms Inc	marketed	PDE-4 inhibitor	Phosphodiesterase 4 (PDE-4)	2016-01-01
Roflumilast conventional dosage	Roflumilast conventional dosage	Asan Medical Center	marketed	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
metformin and roflumilast	metformin and roflumilast	University Medical Centre Ljubljana	marketed	Combination therapy: biguanide and phosphodiesterase-4 inhibitor	Metformin: mitochondrial glycerophosphate dehydrogenase; Roflumilast: phosphodiesterase-4 (PDE-4)
Oral roflumilast	Oral roflumilast	The University of Hong Kong	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Roflumilast Foam	Roflumilast Foam	Arcutis Biotherapeutics, Inc.	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Roflumilast Foam 0.3%	Roflumilast Foam 0.3%	Arcutis Biotherapeutics, Inc.	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-4 (PDE-4) inhibitor class)

Arcutis Biotherapeutics, Inc. · 3 drugs in this class
Amgen · 1 drug in this class
Asan Medical Center · 1 drug in this class
The University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo-Apremilast — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-apremilast. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab